Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Baker

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Epilepsia|August 29, 2023
Genetic influences on epilepsy outcomes: A whole-exome sequencing and health care records data linkage studyBeata Fonferko-Shadrach, Arron S Lacey, Huw Strafford, et al.
Human Reproduction (Oxford, England)|September 2, 2022
17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, is an effective spermicide and microbicide against Neisseria gonorrhoeaeSeung Gee Lee, Wongsakorn Kiattiburut, Thitiporn Khongkha, et al.
British Journal of Clinical Pharmacology|June 13, 2022
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjectsKelong Han, Mark Baker, Mark Lovern, et al.
HIV Medicine|November 22, 2022
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trialsParul Patel, Susan L Ford, Mark Baker, et al.
Clinical and Translational Medicine|June 18, 2024
KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenomaQin Xu, Ting La, Kaihong Ye, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2016
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug DevelopmentJames S McCarthy, Louise Marquart, Silvana Sekuloski, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2025
SNORD80-guided 2'-O-methylation stabilizes the lncRNA GAS5 to regulate cellular stress responsesLiang Xu, Xiao Hong Zhao, Yuan Yuan Zhang, et al.
Complex Psychiatry|August 26, 2022
Neuropsychiatric Genetics of Psychosis in the Mexican Population: A Genome-Wide Association Study Protocol for Schizophrenia, Schizoaffective, and Bipolar Disorder Patients and ControlsBeatriz Camarena, Elizabeth G Atkinson, Mark Baker, et al.
The Lancet. Infectious Diseases|June 18, 2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyAlejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Epilepsia|August 29, 2023
Genetic influences on epilepsy outcomes: A whole-exome sequencing and health care records data linkage studyBeata Fonferko-Shadrach, Arron S Lacey, Huw Strafford, et al.
Human Reproduction (Oxford, England)|September 2, 2022
17BIPHE2, an engineered cathelicidin antimicrobial peptide with low susceptibility to proteases, is an effective spermicide and microbicide against Neisseria gonorrhoeaeSeung Gee Lee, Wongsakorn Kiattiburut, Thitiporn Khongkha, et al.
British Journal of Clinical Pharmacology|June 13, 2022
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjectsKelong Han, Mark Baker, Mark Lovern, et al.
HIV Medicine|November 22, 2022
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trialsParul Patel, Susan L Ford, Mark Baker, et al.
Clinical and Translational Medicine|June 18, 2024
KMT2A and chronic inflammation as potential drivers of sporadic parathyroid adenomaQin Xu, Ting La, Kaihong Ye, et al.
Antimicrobial Agents and Chemotherapy|April 6, 2016
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug DevelopmentJames S McCarthy, Louise Marquart, Silvana Sekuloski, et al.
Clinical Pharmacokinetics|August 21, 2023
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and AdolescentsHardik Chandasana, Mita Thapar, Siobhan Hayes, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 13, 2025
SNORD80-guided 2'-O-methylation stabilizes the lncRNA GAS5 to regulate cellular stress responsesLiang Xu, Xiao Hong Zhao, Yuan Yuan Zhang, et al.
Complex Psychiatry|August 26, 2022
Neuropsychiatric Genetics of Psychosis in the Mexican Population: A Genome-Wide Association Study Protocol for Schizophrenia, Schizoaffective, and Bipolar Disorder Patients and ControlsBeatriz Camarena, Elizabeth G Atkinson, Mark Baker, et al.
The Lancet. Infectious Diseases|June 18, 2018
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyAlejandro Llanos-Cuentas, Martin Casapia, Raúl Chuquiyauri, et al.
Pageof 17